SuperworthPluri EPS PLUR
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $36.65
- Latest quarter, Q4 FY26
- $38.56
- −37% on a year earlier
- Fiscal year 2026
- $36.65
- −38% on the year before
Pluri's earnings per share was $36.65 over the twelve months to Jun 30, 2026, down 38% on a year earlier.
In its latest quarter, Q4 FY26, it was $38.56, down 37% on the same quarter a year before.
Over the five fiscal years to FY2026 it grew 27% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | $36.65 | −38% |
| FY2025 | $59.05 | n/a |
| FY2024 | −$3.99 | −181% |
| FY2023 | $4.95 | −51% |
| FY2022 | $10.08 | −9% |
| FY2021 | $11.12 | n/a |
| FY2020 | −$12.96 | n/a |
| FY2019 | −$23.28 | n/a |
| FY2018 | −$20.00 | n/a |
| FY2017 | −$25.60 | n/a |
| FY2016 | −$23.20 | n/a |
| FY2015 | −$28.00 | n/a |
| FY2014 | −$33.60 | n/a |
| FY2013 | −$30.40 | n/a |
| FY2012 | −$27.20 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY26 | $38.56 | −37% | $36.65 | |
| Q3 FY26 | −$0.55 | n/a | $59.69 | |
| Q2 FY26 | −$0.71 | n/a | $59.30 | |
| Q1 FY26 | −$0.65 | n/a | $59.48 | |
| Q4 FY25 | $61.60 | n/a | $59.05 | |
| Q3 FY25 | −$0.94 | n/a | −$3.61 | |
| Q2 FY25 | −$0.53 | n/a | −$3.68 | |
| Q1 FY25 | −$1.08 | n/a | −$4.11 | |
| Q4 FY24 | −$1.06 | −111% | −$3.99 | |
| Q3 FY24 | −$1.01 | n/a | $6.99 | |
| Q2 FY24 | −$0.96 | n/a | $6.47 | |
| Q1 FY24 | −$0.96 | n/a | $5.51 |
Against its peers
Companies in Healthcare nearest Pluri's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PLURPluri | $36.65 | −38% a year |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| Peer median | $0.36 |
Where Pluri ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Pluri
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.